Indian Journal of Rheumatology

REVIEW ARTICLE
Year
: 2020  |  Volume : 15  |  Issue : 6  |  Page : 81--90

The clinicoserological spectrum of inflammatory myopathy in the context of systemic sclerosis and systemic lupus erythematosus


John D Pauling1, Sarah Skeoch1, Julie J Paik2 
1 Royal National Hospital for Rheumatic Diseases (Part of the Royal United Hospitals NHS Foundation Trust); Department of Pharmacy and Pharmacology, University of Bath, Bath, USA
2 Johns Hopkins Myositis Center, 4500 Baltimore, MD, USA

Correspondence Address:
Dr. John D Pauling
Department of Pharmacy and Pharmacology, University of Bath, Bath; Royal National Hospital for Rheumatic Diseases (Part of the Royal United Hospitals NHS Foundation Trust), Bath
USA

Autoimmune rheumatic diseases (ARDs) are characterized by a pathological triad composed of autoimmunity/inflammation, microangiopathy, and aberrant tissue remodeling. Disease terms such as idiopathic inflammatory myopathy (IIM), scleroderma/systemic sclerosis (SSc), and systemic lupus erythematosus (SLE) are helpful clinically but disguise the considerable overlap that exists within these “distinct” disorders. This is perhaps best demonstrated by inflammatory myopathy, which can be present in SSc or SLE, but can itself be absent in clinically amyopathic IIM. Archetypal clinical manifestations of ARD (such as Raynaud's phenomenon) are frequently present, albeit with varying prominence, within each of these diseases. This is certainly the case for inflammatory myositis, which has long been recognized as an important clinical feature of both SSc and SLE. Progress in elucidating the clinicoserological spectrum of ARDs has identified autoantibody specificities that are strongly associated with “overlap” disease and the presence of inflammatory myositis in SSc and SLE. In this review, we shall describe the prevalence, burden, prognostic value, and management considerations of IIM in the context of both SSc and SLE. A major emphasis on the value of autoantibodies shall highlight the value of these tools in predicting the future occurrence of inflammatory myositis in both SSc and SLE. Where applicable, unmet research needs shall be highlighted. The review emphasizes the importance of myopathy as a common feature across all the ARDs and highlights specific antibody specificities that are strongly associated with myopathy in the context of SLE and SSc.


How to cite this article:
Pauling JD, Skeoch S, Paik JJ. The clinicoserological spectrum of inflammatory myopathy in the context of systemic sclerosis and systemic lupus erythematosus.Indian J Rheumatol 2020;15:81-90


How to cite this URL:
Pauling JD, Skeoch S, Paik JJ. The clinicoserological spectrum of inflammatory myopathy in the context of systemic sclerosis and systemic lupus erythematosus. Indian J Rheumatol [serial online] 2020 [cited 2021 Feb 28 ];15:81-90
Available from: https://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=6;spage=81;epage=90;aulast=Pauling;type=0